Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840956 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
A Phase 1 study, sponsored by Humacyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01840956 is a Phase 1 study that has completed, run by Humacyte. The registered enrollment target is 20 participants.
The verdict
NCT01840956, a Phase 1 study, has completed, sponsored by Humacyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG. The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
Interventions
- BIOLOGICAL HAVG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-05-23 |
| Est. Completion | 2016-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01840956
The ClinicalTrials.gov registry entry for NCT01840956 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Humacyte, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HAVG is the first listed.
NCT01840956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01840956 about?
NCT01840956 is a clinical study titled "Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease". The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG. The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
What is the current status of trial NCT01840956?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-05-23. Estimated completion is 2016-04-28.
What interventions are being tested in trial NCT01840956?
The interventions under investigation include: HAVG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01840956?
This trial is sponsored by Humacyte, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.